- Home
- SNDX vs PSFE Comparison
SNDX vs PSFE Comparison
Compare SNDX & PSFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNDX | PSFE |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 461.4M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNDX | PSFE |
|---|---|---|
| Price | $21.30 | $8.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 5 |
| Target Price | ★ $36.92 | $10.60 |
| AVG Volume (30 Days) | ★ 1.7M | 606.0K |
| Earning Date | 11-03-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $111,304,000.00 | ★ $1,683,103,000.00 |
| Revenue This Year | $620.14 | $1.95 |
| Revenue Next Year | $115.42 | $6.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 595.65 | N/A |
| 52 Week Low | $8.58 | $6.43 |
| 52 Week High | $22.73 | $24.11 |
Technical Indicators
Market Signals| Indicator | SNDX | PSFE |
|---|---|---|
| Relative Strength Index (RSI) | 64.62 | 44.76 |
| Support Level | $19.72 | $7.68 |
| Resistance Level | $22.73 | $8.46 |
| Average True Range (ATR) | 0.91 | 0.35 |
| MACD | -0.05 | 0.11 |
| Stochastic Oscillator | 59.94 | 38.14 |
Price Performance
Historical ComparisonAbout SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.